CMMB Stock Forecast 2025-2026
Distance to CMMB Price Targets
CMMB Price Momentum
10 Quality Stocks Worth Considering Now
Researching Chemomab (CMMB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CMMB and similar high-potential opportunities.
Latest CMMB Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CMMB has a bullish consensus with a median price target of $9.00 (ranging from $7.00 to $11.00). Currently trading at $1.10, the median forecast implies a 718.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jeff Jones at Oppenheimer, projecting a 900.0% upside. Conversely, the most conservative target is provided by Michael Okunewitch at Maxim Group, suggesting a 536.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMMB Analyst Ratings
CMMB Price Target Range
Latest CMMB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMMB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 20, 2025 | Maxim Group | Michael Okunewitch | Buy | Maintains | $7.00 |
| Nov 15, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $11.00 |
| May 13, 2024 | Maxim Group | Michael Okunewitch | Buy | Initiates | $4.00 |
| May 6, 2024 | Oppenheimer | Jeff Jones | Outperform | Upgrade | $6.00 |
| Mar 8, 2024 | Oppenheimer | Jeff Jones | Perform | Maintains | $0.00 |
| Dec 19, 2023 | Roth MKM | Dylan Dupuis | Buy | Reinstates | $7.00 |
| Oct 6, 2023 | Roth MKM | Dylan Dupuis | Buy | Initiates | $7.00 |
| Jun 7, 2023 | Oppenheimer | Jeff Jones | Perform | Downgrade | $0.00 |
| Apr 18, 2023 | Oppenheimer | Jeff Jones | Outperform | Maintains | $7.00 |
| Mar 10, 2022 | Oppenheimer | Jeff Jones | Outperform | Maintains | $20.00 |
| Dec 7, 2021 | Aegis Capital | Buy | Initiates | $0.00 | |
| May 26, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| May 7, 2021 | Oppenheimer | Outperform | Initiates | $0.00 |
Chemomab Therapeutics Ltd. (CMMB) Competitors
The following stocks are similar to Chemomab based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Chemomab Therapeutics Ltd. (CMMB) Financial Data
Chemomab Therapeutics Ltd. has a market capitalization of $21.87M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -91.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Chemomab Therapeutics Ltd. (CMMB) Business Model
About Chemomab Therapeutics Ltd.
Develops innovative treatments for inflammation and fibrosis.
The company operates in the biopharmaceutical sector, focusing on the discovery and development of therapies that target inflammation and fibrotic tissues. It generates revenue through the advancement of its drug candidates, which aim to address significant unmet medical needs in conditions like liver fibrosis and systemic sclerosis.
Chemomab Therapeutics is headquartered in Israel, a region renowned for technological innovation, which supports its goal of translating scientific research into effective clinical treatments. The company is committed to addressing serious health challenges with limited treatment options, thereby contributing to advancements in medical care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Dr. Adi Mor George Ph.D.
Country
Israel
IPO Year
2019
Website
www.chemomab.comChemomab Therapeutics Ltd. (CMMB) Latest News & Analysis
Positive 48-week data from Phase 2 PSC trial of nebokitug indicates reduced disease progression risk and improved fibrosis markers.
Positive trial results for nebokitug suggest potential efficacy in treating fibrosis, which could lead to increased market confidence, stock price appreciation, and potential partnerships or acquisitions.
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
17 hours agoChemomab Therapeutics Ltd. (CMMB) announced results from the Open Label Extension of its Phase 2 Spring trial for nebokitug, targeting primary sclerosing cholangitis (PSC).
Chemomab's positive Phase 2 trial results for nebokitug in PSC could enhance its market potential, impacting stock performance and attracting investor interest in biotech innovation.
Chemomab Therapeutics will present new data on nebokitug (CM-101) as a potential treatment for systemic sclerosis at CORA 2025 on March 8, 2025.
Positive data on nebokitug's potential for systemic sclerosis enhances Chemomab's growth prospects, potentially boosting stock value and attracting investor interest in the biotech sector.
In 2024, positive Phase 2 data for nebokitug in treating primary sclerosing cholangitis was reported, indicating a clear pathway for potential FDA approval.
Positive Phase 2 data for nebokitug suggests strong market potential and increased likelihood of FDA approval, likely boosting investor confidence and stock value for the company involved.
Chemomab and the FDA have agreed on a pathway for regulatory approval, requiring a single pivotal Phase 3 study for PSC treatment.
Chemomab's alignment with the FDA on a Phase 3 study increases the likelihood of regulatory approval, potentially boosting the company's stock value and attracting investor interest.
Chemomab Therapeutics will present at Oppenheimer's Rare Disease Summit on December 12, 2024, highlighting potential stock-moving catalysts for its fibro-inflammatory disease treatments.
Elevator pitches from rare disease companies at the summit may highlight potential breakthroughs, influencing stock prices and attracting investor interest in biotech firms like Chemomab.
Frequently Asked Questions About CMMB Stock
What is Chemomab Therapeutics Ltd.'s (CMMB) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Chemomab Therapeutics Ltd. (CMMB) has a median price target of $9.00. The highest price target is $11.00 and the lowest is $7.00.
Is CMMB stock a good investment in 2025?
According to current analyst ratings, CMMB has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMMB stock?
Wall Street analysts predict CMMB stock could reach $9.00 in the next 12 months. This represents a 718.2% increase from the current price of $1.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chemomab Therapeutics Ltd.'s business model?
The company operates in the biopharmaceutical sector, focusing on the discovery and development of therapies that target inflammation and fibrotic tissues. It generates revenue through the advancement of its drug candidates, which aim to address significant unmet medical needs in conditions like liver fibrosis and systemic sclerosis.
What is the highest forecasted price for CMMB Chemomab Therapeutics Ltd.?
The highest price target for CMMB is $11.00 from Jeff Jones at Oppenheimer, which represents a 900.0% increase from the current price of $1.10.
What is the lowest forecasted price for CMMB Chemomab Therapeutics Ltd.?
The lowest price target for CMMB is $7.00 from Michael Okunewitch at Maxim Group, which represents a 536.4% increase from the current price of $1.10.
What is the overall CMMB consensus from analysts for Chemomab Therapeutics Ltd.?
The overall analyst consensus for CMMB is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are CMMB stock price projections?
Stock price projections, including those for Chemomab Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
